🇺🇸 FDA

Intelligence · Patent portfolio

Teva Pharma Patents

Full USPTO pharma patent portfolio for Teva Pharma — grant dates, expiration, and drug cross-links.

Patents
454
Expiring ≤24m
49

Quick answer

Teva Pharma has 454 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 49 expire within 24 months — use filters for patent-cliff planning.

Page 4 of 10

  1. US 8614252

    Crystalline solid rasagiline base

    Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8609856

    Crystalline forms of Febuxostat

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8598203

    Treatment of Crohn's disease with laquinimod

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8597666

    Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8592442

    Nilotinib HCl crystalline forms

    Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8580819

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8580293

    Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

    Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8569379

    Use of rasagiline for the treatment of olfactory dysfunction

    Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8563014

    Modafinil oral lyophilizate

    Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8545885

    Stable laquinimod preparations

    Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8541373

    BChE albumin fusions for the treatment of cocaine abuse

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8536149

    TRPM-2 antisense therapy

    Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8501766

    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8487097

    Reference standard for characterization of rosuvastatin

    Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8470344

    Aqueous dispersions and solutions of difficult to dissolve materials and methods of their preparation

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8450299

    Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

    Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8426474

    Antimicrobial wash and carrier solutions and uses thereof

    Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8415332

    Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8415314

    Methods for treating multiple sclerosis using antisense oligonucleotides

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8415481

    Crystalline form of febuxostat

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8414918

    Stable imatinib compositions

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8414920

    Pharmaceutical composition containing irbesartan

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8410267

    Regioselective reduction of fused pyrrolocarbazoles-5,7-diones

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8410288

    Polymorphs of Saxagliptin hydrochloride and processes for preparing them

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8389228

    Process for the measurement of the potency of glatiramer acetate

    Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8383645

    Stable laquinimod preparations

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8367106

    Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

    Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8367105

    Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

    Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8338396

    Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8334409

    Process for purifying rasagiline base

    Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8329696

    Solid state forms of sitagliptin salts

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8323634

    Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8323679

    Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8288342

    Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8252933

    2-oxo-1,2-dihydro-quinoline modulators of immune function

    Expires Mon Aug 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8247393

    Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

    Expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8226977

    Pharmaceutical composition containing irbesartan

    Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8226980

    Orally disintegrating solid dosage forms comprising progestin and methods of making and using thereof

    Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8222282

    Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine

    Expires Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8217024

    Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

    Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8207361

    Tigecycline crystalline forms and processes for preparation thereof

    Expires Mon Jun 21 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8202534

    Attachment of a handle to a solid oral dosage form

    Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8198470

    Crystalline form II of tigecycline and processes for preparation thereof

    Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8198469

    Crystalline forms of tigecycline and processes for preparation thereof

    Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8188149

    Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8188067

    Formulations of 6-mercaptopurine

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8183373

    Solid state forms of sitagliptin salts

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8178127

    Stable laquinimod preparations

    Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Teva Pharma have?

454 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Teva Pharma patents expire?

49 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.